CY1107393T1 - Τροποποιημενα env πολυπεπτιδια του hiv - Google Patents

Τροποποιημενα env πολυπεπτιδια του hiv

Info

Publication number
CY1107393T1
CY1107393T1 CY20081100418T CY081100418T CY1107393T1 CY 1107393 T1 CY1107393 T1 CY 1107393T1 CY 20081100418 T CY20081100418 T CY 20081100418T CY 081100418 T CY081100418 T CY 081100418T CY 1107393 T1 CY1107393 T1 CY 1107393T1
Authority
CY
Cyprus
Prior art keywords
hiv polypeptides
polypeptides
modified env
env hiv
modified
Prior art date
Application number
CY20081100418T
Other languages
English (en)
Inventor
Susan Barnett
Karin Hartog
Eric Martin
Original Assignee
Novartis Vaccines And Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26812260&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107393(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines And Diagnostics, Inc. filed Critical Novartis Vaccines And Diagnostics, Inc.
Publication of CY1107393T1 publication Critical patent/CY1107393T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αποκαλύπτονται πολυνουκλεοτίδια που κωδικεύουν τροποποιημένα HIV Env πολυπεπτίδια. Τα Env πολυπεπτίδια είναι τροποποιημένα έτσι ώστε να εκθέτουν τουλάχιστον μέρος της CD4 περιοχής πρόσδεσης. Παρέχονται επίσης μέθοδοι διάγνωσης, θεραπείας και πρόληψης όπου χρησιμοποιούνται τα πολυνουκλεοτίδια και πολυπεπτίδια.
CY20081100418T 1998-12-31 2008-04-15 Τροποποιημενα env πολυπεπτιδια του hiv CY1107393T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11449598P 1998-12-31 1998-12-31
US15667099P 1999-09-29 1999-09-29
EP99968574A EP1141315B1 (en) 1998-12-31 1999-12-30 Modified hiv env polypeptides

Publications (1)

Publication Number Publication Date
CY1107393T1 true CY1107393T1 (el) 2012-12-19

Family

ID=26812260

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100418T CY1107393T1 (el) 1998-12-31 2008-04-15 Τροποποιημενα env πολυπεπτιδια του hiv

Country Status (12)

Country Link
US (3) US6689879B2 (el)
EP (1) EP1141315B1 (el)
JP (1) JP4776075B2 (el)
AT (1) ATE384795T1 (el)
AU (1) AU2596600A (el)
CA (1) CA2358915C (el)
CY (1) CY1107393T1 (el)
DE (1) DE69938062T2 (el)
DK (1) DK1141315T3 (el)
ES (1) ES2299276T3 (el)
PT (1) PT1141315E (el)
WO (1) WO2000039303A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
EP2280074A3 (en) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) * 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AU2003301556A1 (en) 2002-05-07 2004-05-13 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
AU2003282498A1 (en) 2002-10-07 2004-05-04 Chiron Corporation Hiv vaccine formulations
WO2005027840A2 (en) * 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
US7622125B2 (en) * 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
SG153796A1 (en) 2004-06-08 2009-07-29 Novartis Vaccines & Diagnostic Fusion proteins comprising cd4 minimal modules and methods of use thereof
WO2007018550A2 (en) * 2004-09-08 2007-02-15 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Compositions and methods for the detection of hiv-1/hiv-2 infection
WO2006050394A2 (en) * 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
ATE471947T1 (de) 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CN101591379B (zh) * 2008-05-27 2017-01-18 中国疾病预防控制中心性病艾滋病预防控制中心 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
AU2012340035A1 (en) 2011-11-14 2014-04-17 Susan W. Barnett Immunogenic complexes of polyanionic carbomers and Env polypeptides and methods of manufacture and use thereof
EP3189067B1 (en) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
EP3380605A1 (en) 2015-11-24 2018-10-03 GlaxoSmithKline Intellectual Property Development Limited Transient transfection method for retroviral production
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US8785609B1 (en) * 1984-08-22 2014-07-22 United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5032510A (en) 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
EP0203177A4 (en) 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES AGAINST DEGGLYCOSILIZED VIRAL GLYCOPROTEINS.
AU600658B2 (en) 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
DK171119B1 (da) 1985-04-19 1996-06-17 Hoffmann La Roche AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin
JPS63501716A (ja) 1985-10-24 1988-07-14 サウスウエスト・ファウンデ−ション・フォア・バイオメディカル・リサ−チ 合成ペプチドおよびａｉｄｓおよびａｒｃの診断ならびにワクチン注射へのその使用
EP0242216A1 (en) 1986-04-16 1987-10-21 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Non-cytopathic clone of Human T-Cell Lymphotropic Virus type III
AU7786387A (en) 1986-07-21 1988-02-10 Southwest Foundation For Biomedical Research Composition of matter and method of immunizing against viral causative agents of aids and arc
US4861707A (en) 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
ES2167304T3 (es) 1987-06-22 2002-05-16 Medeva Holdings Bv Peptido que contiene el antigeno de superficie de la hepatitis b.
US5637677A (en) 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
WO1989002277A2 (en) 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
JPH02501192A (ja) 1987-09-04 1990-04-26 バイオジェン インコーポレイテッド 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
US5879907A (en) 1987-09-14 1999-03-09 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof and method
NZ226414A (en) 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
US5714596A (en) 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5683864A (en) 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5712088A (en) 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
CA1340748C (en) 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
ATE112687T1 (de) 1988-09-13 1994-10-15 Chiron Corp Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
KR900701836A (ko) 1988-10-03 1990-12-04 라메쉬 엘. 라탄 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL93682A (en) 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
WO1990011359A1 (en) 1989-03-20 1990-10-04 Whitehead Institute For Biomedical Research Intracellular method of inhibiting hiv in mammalian cells
EP0465529B1 (en) 1989-03-21 1998-04-29 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
WO1990012094A1 (en) 1989-04-05 1990-10-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A clone of double-stranded rna virus and applications thereof
DK0431128T3 (da) 1989-06-01 2004-06-28 Therion Biolog Corp Vektor, der koder for selvsamlende, defekte, ikke-selvopformerende viruspartikler
US5130247A (en) 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
EP0493508A1 (en) 1989-09-22 1992-07-08 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
EP0424748B1 (en) 1989-10-23 1995-05-10 F. Hoffmann-La Roche Ag Synthetic envelope peptides of HTLV-I
EP0839536A1 (en) 1989-10-27 1998-05-06 Arch Development Corporation Methods and compositions for promoting immunopotentiation
AU6965591A (en) 1989-11-17 1991-06-13 Amgen, Inc. A method of detecting htlv-i antibodies in human body fluids
HUT60506A (en) 1989-11-20 1992-09-28 Oncogen Process for producing non-replicable, recombinant retrovirus particles and antiviral and immunogenic preparations
SE468168B (sv) 1990-02-20 1992-11-16 Replico Medical Ab Hiv-1, p24 peptider, diagnostiska antigener och foerfarande foer saerskiljande diagnostik av preliminaert hiv-1 positiva serumprov
IE910779A1 (en) 1990-03-09 1991-09-11 Chiron Corp PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
US5876724A (en) 1990-03-19 1999-03-02 Institut Pasteur Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
ATE183235T1 (de) 1990-03-21 1999-08-15 Wolf Hans Joachim Prof Dr Für abgeänderte retrovirale gag-polypeptide kodierende dna-sequenzen und diese enthaltende impfstoffe oder aggregate davon
EP0527760B1 (en) 1990-04-03 1995-07-19 Genentech, Inc. Methods and compositions for vaccination against hiv
EP0527789A1 (en) 1990-04-03 1993-02-24 Genentech, Inc. Hiv envelope polypeptides
IL97985A0 (en) 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
AP237A (en) 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
WO1991019803A1 (en) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
SE470074B (sv) 1990-08-16 1993-11-01 Replico Medical Ab Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider
AU641554B2 (en) 1990-08-29 1993-09-23 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Novel peptide antigens and immunoassays, test kits and vaccines using the same
US5840313A (en) 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
WO1992005799A1 (en) 1990-09-28 1992-04-16 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
PT100090A (pt) 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
WO1992015318A1 (en) 1991-03-07 1992-09-17 Seragen, Inc. Use of cell surface receptor targeted molecules for the treatment of viral diseases
WO1993002102A1 (en) 1991-07-23 1993-02-04 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Novel peptide antigens and immunoassays, test kits and vaccines using the same
US5665569A (en) 1991-08-22 1997-09-09 Nissin Shokuhin Kabushiki Kaisha HIV immunotherapeutics
WO1993004090A1 (en) 1991-08-22 1993-03-04 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
ES2182822T3 (es) 1991-09-13 2003-03-16 Chiron Corp Composiciones de polipeptidos inmunorreactivos del virus de la hepatitis c.
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
US5686078A (en) 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
CA2105629A1 (en) 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
US5304472A (en) 1992-11-20 1994-04-19 Genentech, Inc. Method of controlling polypeptide production in bacterial cells
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1994016081A1 (de) 1993-01-16 1994-07-21 Manfred Schawaller Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
KR100325554B1 (ko) 1993-03-26 2002-11-02 젠-프로브 인코포레이티드 사람의면역결핍 바이러스타입1의검출
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5864027A (en) * 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
BR9406821A (pt) 1993-06-09 1996-03-26 Connaught Lab Peptideo sintético composiçao imunogenica kit de diagnostico útil para dectar anticorpos especificos de hiv em amostra de teste kit de diagnostico para detectar antigenos de hiv em amostra de teste codificaçao de molécula de ácido nucléico e anticorpo
US5614413A (en) 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US5955342A (en) 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US6291157B1 (en) 1998-02-23 2001-09-18 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5550280A (en) 1994-11-30 1996-08-27 Uniroyal Chemical Ltd./ Uniroyal Chemical Ltee Hindered aromatic ester compounds useful as anti-viral agents
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5741492A (en) 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US6087486A (en) 1996-01-29 2000-07-11 The Trustees Of The University Of Pennsylvania Nucleotide sequences encoding vpr receptor protein
US5951975A (en) 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
ATE229073T1 (de) 1996-09-06 2002-12-15 Univ California Protein e25a, methoden zu dessen herstellung und anwendung
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US5858675A (en) 1997-05-13 1999-01-12 Incyte Pharmaceuticals, Inc. Double-stranded RNA-binding protein
US6099847A (en) 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
US5932442A (en) 1997-09-23 1999-08-03 Incyte Pharmaceuticals, Inc. Human regulatory molecules
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
CA2325560A1 (en) 1998-04-14 1999-10-21 Chiron Corporation Noncloning technique for expressing a gene of interest
US6090388A (en) 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AU2400500A (en) 1999-11-01 2001-05-14 Chiron Corporation Expression vectors, transfection systems, and method of use thereof

Also Published As

Publication number Publication date
WO2000039303A2 (en) 2000-07-06
AU2596600A (en) 2000-07-31
EP1141315A2 (en) 2001-10-10
US20100092502A1 (en) 2010-04-15
EP1141315B1 (en) 2008-01-23
US20020146683A1 (en) 2002-10-10
US20090304740A1 (en) 2009-12-10
JP4776075B2 (ja) 2011-09-21
DE69938062D1 (de) 2008-03-13
DK1141315T3 (da) 2008-05-19
DE69938062T2 (de) 2009-01-15
CA2358915C (en) 2010-06-01
US6689879B2 (en) 2004-02-10
ATE384795T1 (de) 2008-02-15
WO2000039303A3 (en) 2000-09-21
CA2358915A1 (en) 2000-07-06
US7662916B2 (en) 2010-02-16
JP2002533125A (ja) 2002-10-08
ES2299276T3 (es) 2008-05-16
PT1141315E (pt) 2008-05-05

Similar Documents

Publication Publication Date Title
CY1107393T1 (el) Τροποποιημενα env πολυπεπτιδια του hiv
TR200001544T2 (tr) Yeni bileşikler.
TR199801418T2 (xx) Rekombinant a�� vekt�rleri kar���m�.
NO911694D0 (no) Mikroemulsjonsblanding til haarbehandling, fremgangsmaate for fremstilling og anvendelse derav.
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
NO963462L (no) Paramunitetinducer basert på kombinasjoner av poxvirus komponenter, fremgangsmåte for fremstilling derav og anvendelse som medikament
MX3173A (es) Complejos de flavanolignanos/fosfolipidos y procedimiento de obtencion.
NO871025L (no) Polypeptid, dna og fremgangsmaate for fremstilling derav.
DE68922206T2 (de) NETBIOS-Namenauthentisierung.
TR22663A (tr) Yueksek cis muntevah,yueksek molekuel a girhkh ve esash derecede gel bulunmayan isopren polimer ve kopolimerlerinin hazirlanmasi icin bir usul
GR1000850B (el) Διαλυτα ανθρωπινα τεμαχια cd4 και οι χρησεις τους.
FR2731013B1 (fr) Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
CY1109812T1 (el) Αντιγονικα πολυπεπτιδια neisseira meningitidis (μηνιγγιτιδοκοκκου), αντιστοιχα πολυνουκλεοτιδια και προστατευτικα αντισωματα
NO875358L (no) 6-benzoksazinyl- og 6-benzotiazinyl-2,3,4,5-tetrahydropyridazin-3-oner og fremgangsmaate for deres fremstilling.
DE69938935D1 (de) Zyklische conotoxin-peptide
NO874723D0 (no) Forgrende polyoksalkylenblandingspolyestere, fremgangsmaate til deres fremstilling og deres anvendelse.
ES544787A0 (es) Preparaciones medicinales solidas
EP0222302A3 (en) Strain of aureobasidium pullulans, preparation process and use
DE3670043D1 (de) Gelenkhebel-, schneid- und umformpresse.
TR200001745T2 (tr) Keton peroksit türevleri, bunların hazırlanması ve kullanılması
NO984540L (no) Cytokrom P450 transduserende retrovirusvektorer
GT199900062A (es) Preparados efervescentes.
FI850304A0 (fi) Indolofenathridiner.
DE308298T1 (de) Panzerung, insbesondere fuer tresore, und damit versehene tresoren.